ELTP Catalysts:
Next 1day-6 months:
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $4.7 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
X 26. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
X 27. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
__28. Generate revenues over $20 million/quarter
__29. Final Approval of New Manufacturing Facility/Expansion
__30. Double output of manufacturing and packaging facilities
X 31. Launch approved generic Tylenol with Codeine $47 Million
__32. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__33. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__34. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
X 35. Godzilla -Generic Vyvanse Approval $4.3 Billion
__36. Positive BE Study for Concerta CNS Stimulant $1.2 Billion
__37. Godzilla - Generic Vyvance LAUNCH $4.3 Billion
__38. Generic Concerta- FDA submission $1.2 Billion
__39. Launch Adderall IR in Israel
__40. 100 million in yearly revenues
__41. Generic OxyContin Tentative Approval $720 Million
__42. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__43. Launch generic OxyContin $720 Million
__44. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone - Game Over Drug
__45. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__46. $200 million in yearly revenue
__47. Patented NDA Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__48. Undisclosed Mikah ANDA(s)
__49. Undisclosed ANDAs/NDAs
__50. Generic Concerta Launch $1.2 Billion
__51. DollarLand PPS
__52. Big Pharma bidding
__53. UpList to the NASDAQ Exchange
__54. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__55. Vegas BABY !!!!!
Bullish
BULLISH
AI
